September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The severe neovascular phenotype of a mouse model for Coats-like vasculopathy, rnv3, is dependent on Crb1rd8
Author Affiliations & Notes
  • Patsy M Nishina
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Benjamin Low
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Jieping Wang
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Bernard FitzMaurice
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Michael Wiles
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Bo Chang
    Research, The Jackson Laboratory, Bar Harbor, Maine, United States
  • Footnotes
    Commercial Relationships   Patsy Nishina, None; Benjamin Low, None; Jieping Wang, None; Bernard FitzMaurice, None; Michael Wiles, None; Bo Chang, None
  • Footnotes
    Support  NIH Grants EY016501, EY019943, P30 CA034196
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2627. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Patsy M Nishina, Benjamin Low, Jieping Wang, Bernard FitzMaurice, Michael Wiles, Bo Chang; The severe neovascular phenotype of a mouse model for Coats-like vasculopathy, rnv3, is dependent on Crb1rd8. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2627.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To identify the genetic basis of rnv3 (previously reported as JR5558 and Nrv2), a mutant with an early-onset retinal neovascular phenotype.

Methods : Longitudinal analysis by fundus examination, brightfield fundus imaging, fluorescein angiography and optical coherence tomography (OCT) was carried out on live animals, and histology was performed at various ages. The rnv3 mutation was mapped in a linkage cross using polymorphic markers. An exome capture library generated from a rnv3 mutant was subject to high-throughput sequencing and analysis. The mutation was corrected directly in zygotes, using TALEN and oligonucleotide homology directed repair.

Results : OCT indicated lesions in the subretinal space and fluorescein angiography indicated aberrant vessels with leakage. Histologically, retinal vessels span the outer retina and form lesions in the subretinal space as early as 3 weeks of age. Marker analysis indicated fragmentation of the external limiting membrane. The rnv3 phenotype mapped to Chr.1. Examination of sequences within the critical region indicated a mutation in the Crb1 gene; the same mutation reported for Crb1rd8. TALEN mediated correction of the Crb1rd8 allele, Crb1corrrd8 in the homozygous rnv3 genetic background showed a 90% bilateral reduction in the number of neovascular lesions compared to uncorrected rnv3 mutant fundus images.

Conclusions : Genetic analysis has linked mutations in CRB1 with many retinal diseases including retinitis pigmentosa (RP) with para-arteriolar preservation of the RPE, RP with Coats-like exudative vasculopathy, Leber congenital amaurosis, pigmented paravenous retinochoroidal atrophy and macular dystrophy. A large degree of variation is also seen both in the age of onset and the severity of vision loss among patients with CRB1 variants. Our results indicate that Crb1rd8 is necessary for the severe neovascular abnormalities in rnv3 mutants, as only a low incidence of neovascular lesions is observed among corrected mice. Since some neovascular lesions were still observed, and B6/J.Cg-Crb1rd8/rd8 and B6/NJ-Crb1rd8/rd8 mice normally do not present with neovascular lesions at three weeks, this suggests that additional gene(s) must interact with Crb1rd8 to cause early, aberrant vessel formation. Hence, yet unidentified genes in the rnv3 genetic background result in a neovascular phenotype that is dramatically increased by the Crb1rd8 mutation.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×